CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
Mecamylamine +1 moredrug
Likely dose
Mecamylamine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00563797
NCT00563797Phase 3Completed
CompareCT.gov

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Yale University·interventional·Posted Nov 26, 2007·Updated Apr 18, 2016

In Brief

A Phase 3 clinical trial evaluating Mecamylamine and Placebo for Alcohol Dependence and Depression. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day) versus placebo in reducing depressive and alcohol symptoms in patients with depression and co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce depressive symptoms and decrease alcohol consumption compared to placebo in patients with depression and alcohol dependence who are on a stable dose of a selective serotonin reuptake inhibitor (SSRI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence, Depression
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 26, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 18.6 years ago

Interventions

Mecamylaminedrug

mecamylamine 10mg/day for 12 weeks

Placebodrug

Placebo pill